GC Times Talk

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus. This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.   New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

By 2030, diabetes will be the 7th leading cause of premature mortality worldwide, according to the World Health Organisation. The application of nanotechnology in medicine holds many possible advantages and over the past few decades, there has been huge progress in its utilisation. Nanotechnology is widely applied for cancer treatment and other diseases but, the use of it for diabetes treatment is now starting to flourish. This book presents the latest developments of nanomedicine for the treatment of different facets of diabetes and related disorders. With a multidisciplinary approach, chapters focus on previously overlooked topics in glucose sensing, insulin delivery and secretion, bioimaging and transplantation of islets. This book is suitable for researchers of nanomedicine, nanotechnology and diabetes looking into the emergence of new approaches for the treatment of this life-threatening disease.

Diabetes is a chronic disease involving self-management by the patients. This book teaches providers the skills to translate and transfer complex medical information to empower patients to participate in making well-informed decisions about their own care on a daily basis, as directed by the American Diabetes Association. It provides the basic knowledge around the pathophysiology of diabetes, different management options including insulin management and calculations, information on how foods affect blood sugars and how to address cardiovascular risk factors. This book aims to change clinical outcomes through its unique presentation of information and its approach to awareness. Key Features Follows a unique approach in imparting techniques that bring long-term patient behaviour changes, making the provision of chronic disease management more efficient and satisfying Serves to help professionals in their day-to-day patient management to achieve better outcomes Addresses the area of need for primary care and helps to make well-informed decisions by understanding the essential cost of care

This book is designed to be a ready reckoner on commonly used medications for the treatment of diabetes mellitus. Divided into 17 sections, topics include incretin-based therapies, insulin, chloroquine, metformin, colesevelam, drugs targeting renal excretion of glucose, management of dyslipidaemia, and more. The book concludes with discussion on associated comorbidities such as hypertension and diabetes in the elderly. Drug classes featured are all approved in-line with FDA (United States Food and Drug Administration) guidelines. Authored by recognised, US-based experts in the field, the comprehensive text is further enhanced by clinical photographs, diagrams and tables. Key points Comprehensive guide to pharmaceutical treatments for diabetes mellitus Features approved drugs in-line with FDA (United States Food and Drug Administration) guidelines Includes discussion on commonly associated comorbidities such as hypertension, and diabetes in the elderly Internationally recognised, US-based author team